The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BCLI | N/A | N/A | N/A | -88% |
| S&P | +13.19% | +87.83% | +13.42% | +606% |
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer’s disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.05M | 18.6% |
| Market Cap | $7.34M | 0.0% |
| Market Cap / Employee | $0.27M | 0.0% |
| Employees | 27 | -6.9% |
| Net Income | -$2.11M | 22.2% |
| EBITDA | -$2.00M | 33.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.01M | -97.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.05M | -81.5% |
| Short Term Debt | $0.38M | -33.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -637.06% | -267.8% |
| Return On Invested Capital | 1466.79% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.10M | 66.6% |
| Operating Free Cash Flow | -$1.10M | 66.6% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Book | -1.18 | - | |||
| Price to Tangible Book Value | -1.18 | - | |||
| Enterprise Value to EBITDA | -4.71 | -2.67 | -3.73 | -4.11 | -35.43% |
| Total Debt | $1.02M | $1.77M | $0.58M | $0.43M | -49.23% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
